vVARDIS priced its IPO at $18 per share, selling about 9.72 million shares and raising approximately $175 million ahead of its NYSE debut. The company said the proceeds would fund expansion of its drill-free cavity treatment. Its Curodont Repair Fluoride Plus product has treated over 2.5 million teeth and is used in more than 20% of U.S. dental practices.
vVARDIS shares fall 8.33% in first trading session
vVARDIS completed a $175 million IPO at $18 per Class A share, and its shares fell 8.33% to about $16.50 in the first trading session. The company also filed a $76.1 million shelf registration tied to an ESOP offering. The article said limited financial history made it difficult to assess the company using standard valuation measures.